Celularity's abstract, titled “Tri-layer decellularized, dehydrated human amniotic membrane supports proliferation and stemness of limbal stem cells derived from induced pluripotent stem cells,” has been selected for presentation at the 12th World Biomaterials Congress (WBC) in Daegu, Republic of Korea, scheduled for May 26-31, 2024. Hosted by the Korean Society for Biomaterials (KSBM), WBC 2024 focuses on "Convergence in Biomaterials: a vision for the future of healthcare."
LSCD is a debilitating ocular disorder characterized by the loss or dysfunction of limbal stem cells (LSCs), crucial for corneal epithelial regeneration. Celularity’s investigation into utilizing its biomaterial to deliver iPSC-LSCs aims to address this unmet medical need. The integration of iPSC-LSCs with Celularity's biomaterial holds potential for improving patient access to LSCD treatment and managing other ocular surface disorders effectively.
Dr. Robert J. Hariri, Chairman, CEO, and Founder of Celularity, emphasized the significance of this research in advancing ocular regenerative medicine: “Celularity’s regenerative medicine technologies offer promising solutions for addressing severe ocular surface diseases such as LSCD. Our collaboration with renowned research institutions underscores our commitment to translating innovative discoveries into impactful therapies for patients.”
Dr. Anna Gosiewska, Vice President of Research and Development for Degenerative Diseases at Celularity, highlighted the broader implications of their findings: “The investigation into placental biomaterials in regenerative medicine protocols represents a significant advancement. Combining placental biomaterials with cell-based technologies has the potential to revolutionize the treatment landscape for degenerative diseases and tissue repair.”
Collaborating with Celularity on this groundbreaking research is the Gluck Tissue Engineering Laboratory at North Carolina State University, renowned for its expertise in ocular surface regeneration and corneal tissue engineering. Dr. Jessica M. Gluck, Principal Investigator of the Gluck Lab, expressed enthusiasm about the collaborative effort: “Working with Celularity brings us closer to translating ocular regenerative medicine innovations from the laboratory to clinical practice.”
The study's findings underscore the potential of Celularity's biomaterial technology to advance ocular regenerative medicine and provide novel treatment options for patients suffering from severe ocular surface diseases.
